The facility, which will be located in the NorthPoint Industrial Park, plans to manufacture the MetraClip, a transcatherter mitral valve repair system used to repair primary and secondary mitral regurgitation without open-heart surgery. The device has been implanted in more than 90,000 patients worldwide.
The Chicago-based company told the Indianapolis Business Journal it expects construction to start later this year and the facility to be fully operational by 2021.
The 120,000 square-foot facility will employ as many as 477 people by the end of 2024.
Read the full article here.
More articles on supply chain:
FDA warns of critical medical device shortages
UPS expanding healthcare warehouse, distribution network
FDA warns of blood leak risk with endografts
